These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33583020)

  • 1. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Tsaur G; Popov A; Riger T; Kustanovich A; Solodovnikov A; Shorikov E; Demina A; Verzhbitskaya T; Streneva O; Makarova O; Lapotentova E; Aleinikova O; Miakova N; Boichenko E; Kondratchik K; Ponomareva N; Karachunskiy A; Roumiantsev A; Fechina L
    Br J Haematol; 2021 Jun; 193(6):1151-1156. PubMed ID: 33583020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
    Popov A; Tsaur G; Verzhbitskaya T; Riger T; Permikin Z; Demina A; Mikhailova E; Shorikov E; Arakaev O; Streneva O; Khlebnikova O; Makarova O; Miakova N; Fominikh V; Boichenko E; Kondratchik K; Ponomareva N; Novichkova G; Karachunskiy A; Fechina L
    Br J Haematol; 2023 May; 201(3):510-519. PubMed ID: 34970734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
    Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
    J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
    Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
    Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Fominikh V; Verzhbitskaya T; Riger T; Demina A; Shorikov E; Kustanovich A; Movchan L; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Solodovnikov A; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29860. PubMed ID: 35713168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [THE COMPARISON OF RESULTS OF DETECTION OF MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD AND MARROW IN CHILDREN OF THE FIRST YEAR OF LIFE WITH ACUTE LYMPHOBLASTIC LEUCOSIS].
    Tsaur GA; Riger TO; Popov AM; Nasedkina TV; Kustanovich AM; Solodovnikov AG; Streneva OV; Shorikov EV; Tsvirenko SV; Saveliev LI; Fechina LG
    Klin Lab Diagn; 2015 Apr; 60(4):14-22. PubMed ID: 26189286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation.
    Kato M; Hasegawa D; Koh K; Kato K; Takita J; Inagaki J; Yabe H; Goto H; Adachi S; Hayakawa A; Takeshita Y; Sawada A; Atsuta Y; Kato K
    Br J Haematol; 2015 Feb; 168(4):564-70. PubMed ID: 25302748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
    Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
    Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
    Stutterheim J; de Lorenzo P; van der Sluis IM; Alten J; Ancliffe P; Attarbaschi A; Aversa L; Boer JM; Biondi A; Brethon B; Diaz P; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Leung AW; Locatelli F; Silverman L; Stary J; Szczepanski T; van der Velden VHJ; Vora A; Zuna J; Schrappe M; Valsecchi MG; Pieters R
    Eur J Cancer; 2022 Jan; 160():72-79. PubMed ID: 34785111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
    Yilmaz M; Kantarjian H; Wang X; Khoury JD; Ravandi F; Jorgensen J; Short NJ; Loghavi S; Cortes J; Garcia-Manero G; Kadia T; Sasaki K; Konopleva M; Takahashi K; Wierda W; Jain N; Verstovsek S; Estrov Z; Bose P; Pierce S; Garris R; O'Brien S; Jabbour E
    Am J Hematol; 2020 Feb; 95(2):144-150. PubMed ID: 31682008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Minimal Residual Disease Detection in Infants With
    Stutterheim J; van der Sluis IM; de Lorenzo P; Alten J; Ancliffe P; Attarbaschi A; Brethon B; Biondi A; Campbell M; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Li CK; Lo Nigro L; Locatelli F; Marschalek R; Meyer C; Schrappe M; Stary J; Vora A; Zuna J; van der Velden VHJ; Szczepanski T; Valsecchi MG; Pieters R
    J Clin Oncol; 2021 Feb; 39(6):652-662. PubMed ID: 33405950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Ferrari A; Ghelli Luserna Di Rora A; Domizio C; Papayannidis C; Simonetti G; Maria Hernández-Rivas J; Rondoni M; Giglio F; Abruzzese E; Imovilli A; Iacobucci I; Calistri D; Martinelli G
    Br J Haematol; 2021 Mar; 192(6):e139-e144. PubMed ID: 33314053
    [No Abstract]   [Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia.
    Takachi T; Watanabe T; Miyamura T; Moriya Saito A; Deguchi T; Hori T; Yamada T; Ohmori S; Haba M; Aoki Y; Ishimaru S; Sasaki S; Ohshima J; Iguchi A; Takahashi Y; Hyakuna N; Manabe A; Horibe K; Ishii E; Koh K; Tomizawa D
    Blood Adv; 2021 Oct; 5(19):3891-3899. PubMed ID: 34500465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
    Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Brunet S; Bergua J; Tormo M; García-Boyero R; Sarrà J; Del Potro E; Grande C; Barba P; Bernal T; Amigo ML; Grau J; Cervera J; Feliu E;
    Leuk Lymphoma; 2017 Jan; 58(1):145-152. PubMed ID: 27122129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
    Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE
    Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
    Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
    Peterson JF; Sukov WR; Pitel BA; Smoley SA; Pearce KE; Meyer RG; Williamson CM; Smadbeck JB; Vasmatzis G; Hoppman NL; Greipp PT; Baughn LB; Ketterling RP
    Genes Chromosomes Cancer; 2019 Aug; 58(8):567-577. PubMed ID: 30707474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.